首页> 外文期刊>Biotechnology Progress >Immobilization of Mesenchymal Stem Cells and Monocytes in Biocompatible Microcapsules to Cell Therapy
【24h】

Immobilization of Mesenchymal Stem Cells and Monocytes in Biocompatible Microcapsules to Cell Therapy

机译:生物相容性微胶囊中的间充质干细胞和单核细胞的固定化对细胞治疗的作用

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of cell therapy is to replace,repair,or enhance the function of damaged tissues or organs.Several factors complicate the development of cellular therapies.Of primary importance is protection of the implanted cells from the host's immune system.Cells are encapsulated in selectively semipermeable and biocompatible membranes that block entry of immune mediators but allow outward diffusion of active molecules produced by the cells.The immobilization of mesenchymal stem cells and monocytes,in micrometric (30-60 mu m) alginate-barium microcapsules based on atomization processes,has been achieved successfully.This size is necessary to the administration of microcapsules via injection (Hamilton syringe with a needle size of 100 mu m) and aerosol.Microencapsulated cells survive at least 2 weeks after preparation in vitro.
机译:细胞疗法的目的是替换,修复或增强受损组织或器官的功能。多种因素使细胞疗法的发展复杂化。最重要的是保护植入的细胞免受宿主免疫系统的侵害。具有半透性和生物相容性的膜,可阻止免疫介质进入,但允许细胞产生的活性分子向外扩散。基于雾化过程,将微米级(30-60μm)藻酸盐钡微胶囊固定在间充质干细胞和单核细胞此大小对于通过注射(汉密尔顿针头大小为100μm的注射器)和气雾剂给药的微胶囊是必需的。微囊化的细胞在体外制备后至少可以存活2周。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号